Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob McMurray

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Neurology and Therapy|February 11, 2016
Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of RufinamideRob McMurray, Pasquale Striano
Epilepsy & Behavior : E&B|September 21, 2017
Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry studyMarina Nikanorova, Christian Brandt, Stéphane Auvin, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|January 10, 2018
Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practicePasquale Striano, Rob McMurray, Estevo Santamarina, et al.
Seizure|January 7, 2016
Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOMHajo Hamer, Michel Baulac, Rob McMurray, et al.
Neurology and Therapy|September 26, 2018
Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?Charlotte Lawthom, Jukka Peltola, Rob McMurray, et al.
Seizure|January 26, 2020
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practiceRodrigo Rocamora, Jukka Peltola, Giovanni Assenza, et al.
Neurology and Therapy|May 18, 2019
Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥ 60 Versus < 60 Years: A Subanalysis from the Euro-Esli StudyCharlotte Lawthom, Pedro Bermejo, Dulce Campos, et al.
Epilepsia Open|June 7, 2019
Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303Stéphane Auvin, Betsy Williams, Rob McMurray, et al.
Acta Neurologica Scandinavica|July 22, 2020
Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-EsliFrancisco Sales, João Chaves, Rob McMurray, et al.
Acta Neurologica Scandinavica|September 4, 2018
Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-EsliMartin Holtkamp, Norman Delanty, Francisco Sales, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Neurology and Therapy|February 11, 2016
Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of RufinamideRob McMurray, Pasquale Striano
Epilepsy & Behavior : E&B|September 21, 2017
Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry studyMarina Nikanorova, Christian Brandt, Stéphane Auvin, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|January 10, 2018
Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practicePasquale Striano, Rob McMurray, Estevo Santamarina, et al.
Seizure|January 7, 2016
Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOMHajo Hamer, Michel Baulac, Rob McMurray, et al.
Neurology and Therapy|September 26, 2018
Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?Charlotte Lawthom, Jukka Peltola, Rob McMurray, et al.
Seizure|January 26, 2020
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practiceRodrigo Rocamora, Jukka Peltola, Giovanni Assenza, et al.
Neurology and Therapy|May 18, 2019
Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥ 60 Versus < 60 Years: A Subanalysis from the Euro-Esli StudyCharlotte Lawthom, Pedro Bermejo, Dulce Campos, et al.
Epilepsia Open|June 7, 2019
Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303Stéphane Auvin, Betsy Williams, Rob McMurray, et al.
Acta Neurologica Scandinavica|July 22, 2020
Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-EsliFrancisco Sales, João Chaves, Rob McMurray, et al.
Acta Neurologica Scandinavica|September 4, 2018
Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-EsliMartin Holtkamp, Norman Delanty, Francisco Sales, et al.
Pageof 2